Breast Cancer | Specialty

Dr. Katz on Precision Medicine in Breast Cancer

October 4th 2016

Steven Katz, MD, professor, Internal Medicine, University of Michigan Health System, discusses the incorporation of precision medicine into the treatment paradigm of breast cancer.

TNBC Subgroup Stands to Benefit From Androgen Receptor Antagonists

October 3rd 2016

Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.

Expert Evaluates the Future of Endocrine Therapy in Breast Cancer

October 3rd 2016

Despite its substantial progress, much remains unknown about endocrine therapy as a treatment for breast cancer.

Treatment Paradigm for TNBC Continues to Evolve

October 3rd 2016

With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.

Dr. Van Zee on Estimating Risk For Surgical Options in DCIS

October 1st 2016

Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ.

Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast Cancer

September 30th 2016

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.

Dr. Moran on Techniques to Decrease Toxicities With Radiation in Breast Cancer

September 28th 2016

Meena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses some of the techniques that oncologists can use to decrease the toxicities associated with radiation therapy when treating patients with breast cancer.

Expert Sheds Light on Issues With ASCO-CAP HER2 Guidelines

September 27th 2016

Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.

MRI-Guided Radiation Therapy Modernizes Breast Conservation Methods

September 26th 2016

The major advance of the MRI-guided radiotherapy system is the ability to visualize the lumpectomy cavity before and during the delivery of each treatment.

Dr. Brigid Killelea on Nipple-Sparing Mastectomy for Breast Cancer

September 23rd 2016

Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.

Dr. Anees B. Chagpar on the Hottest Topics in Breast Cancer Management

September 23rd 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, explains some of the most discussed topics in breast cancer. Chagpar was recently the chair at the State of the Science Summit on Breast Cancer held Sept. 15.

Dr. Harigopal on Advances With Breast Cancer Pathology

September 21st 2016

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

Dr. Sanft on HER2-Positive Breast Cancer

September 21st 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

Dr. Hofstatter on Identifying High-Risk Patients in Breast Cancer

September 21st 2016

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses the important factors for identifying potentially high-risk patients in breast cancer.

FDA Accepts Neratinib NDA for HER2-Positive Breast Cancer

September 20th 2016

The FDA has accepted a new drug application for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab.

CHMP Issues Positive Opinion for Palbociclib in HR+/HER2- Breast Cancer

September 17th 2016

The Committee for Medicinal Products for Human Use has recommended approval of palbociclib for patients with HR-positive, HER2-negative metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting, or combined with fulvestrant after progression on endocrine therapy.

Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

September 15th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

Biology of Triple-Negative Breast Cancer Crucial for Most Effective Treatment

September 15th 2016

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

Dr. Cynthia Ma on Immunotherapy in TNBC

September 15th 2016

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast Cancer

September 14th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.